DeepMed Research

The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma

Phase 2

Terminated

Conditions: Adenocarcinoma

Interventions: Drug: Avelumab

First Posted Date: 2016-12-21

Last Posted Date: 2022-04-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 8

Registration Number: NCT03000179

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer

Not Applicable

Terminated

Conditions: Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma

Interventions: Procedure: Bronchoscopy with Bronchoalveolar Lavage
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-10-18

Last Posted Date: 2019-09-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 9

Registration Number: NCT02937402

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Hatha Yoga in Breast Cancer Survivors

Not Applicable

Terminated

Conditions: Breast Carcinoma
Lymphedema

Interventions: Procedure: Yoga
Other: tape measurement of arm
Other: Quality-of-Life Assessment
Other: ldex measurement of arms

First Posted Date: 2016-10-04

Last Posted Date: 2019-03-26

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 27

Registration Number: NCT02923037

Locations: 🇺🇸
Vanderbilt University School of Nursing, Nashville, Tennessee, United States

PET Imaging of Ovarian Carcinoma With 18F-FSPG

Early Phase 1

Withdrawn

Conditions: Stage IIIA Ovarian Cancer
Stage IIIA Primary Peritoneal Cancer
Stage IV Ovarian Cancer
Stage IIIC Fallopian Tube Cancer
Stage IIIC Ovarian Cancer
Stage IIIA Fallopian Tube Cancer
Stage IIIB Ovarian Cancer
Stage IIIB Fallopian Tube Cancer
Stage IIIB Primary Peritoneal Cancer
Stage IIIC Primary Peritoneal Cancer

Interventions: Drug: (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)
Procedure: Positron Emission Tomography
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-08-19

Last Posted Date: 2018-06-06

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT02872519

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Blastoid Variant Mantle Cell Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Follicular Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Hodgkin Lymphoma
Recurrent Follicular Lymphoma
Refractory Hodgkin Lymphoma
Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma

Interventions: Drug: Ibrutinib
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-08-17

Last Posted Date: 2023-10-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 23

Registration Number: NCT02869633

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Hematopoietic Cell Transplantation Recipient
Malignant Neoplasm
Influenza

Interventions: Biological: Trivalent Influenza Vaccine
Biological: Quadrivalent Influenza Vaccine
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-08-09

Last Posted Date: 2024-10-22

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 170

Registration Number: NCT02860039

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
UCSF Children's Hospital, San Francisco, California, United States

and more 6 locations

Visually Enhanced Education About Prostate Cancer

Not Applicable

Completed

Conditions: Stage I Prostate Cancer
Stage II Prostate Cancer
Stage III Prostate Cancer

Interventions: Other: Visually enhanced prostate cancer educational presentation
Other: Standard prostate cancer education presentation

First Posted Date: 2016-07-27

Last Posted Date: 2020-07-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT02846870

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Phase 1

Withdrawn

Conditions: Multiple Endocrine Neoplasia Type 1
Functional Pancreatic Neuroendocrine Tumor
Malignant Somatostatinoma
Metastatic Carcinoid Tumor
Multiple Endocrine Neoplasia Type 2A
Stage IIIA Merkel Cell Carcinoma
Stage IIIB Merkel Cell Carcinoma
Stage IVB Thyroid Gland Medullary Carcinoma
VIP-Producing Neuroendocrine Tumor
Merkel Cell Carcinoma

Interventions: Drug: Capecitabine
Drug: Temozolomide
Drug: Veliparib
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-07-13

Last Posted Date: 2017-09-28

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT02831179

Chemoprevention of Gastric Carcinogenesis

Phase 2

Completed

Conditions: Gastric Cancer
Gastric Intestinal Metaplasia

Interventions: Drug: Eflornithine
Other: Eflornithine placebo

First Posted Date: 2016-06-09

Last Posted Date: 2024-10-16

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 91

Registration Number: NCT02794428

Locations: 🇭🇳
Ministry of Health, Hospital de Occidente, Copán, Honduras
🇵🇷
University of Puerto Rico, Comprehensive Cancer Center, San Juan, Puerto Rico

Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides

Recruiting

Conditions: Refractory Mycosis Fungoides
Recurrent Mycosis Fungoides
Stage II Mycosis Fungoides
Stage III Mycosis Fungoides
Stage I Mycosis Fungoides

Interventions: Other: Quality-of-Life Assessment
Other: Objective Grading of Skin Findings

First Posted Date: 2016-03-08

Last Posted Date: 2025-03-28

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 60

Registration Number: NCT02702310

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy